Date: 2015-11-09
Type of information: Licensing agreement
Compound: oxyntomodulin-based therapies including HM12525A
Company: Janssen Pharmaceuticals, a J&J company (USA - NJ) Hanmi Pharmaceutical (South Korea)
Therapeutic area: Metabolic diseases
Type agreement: licensing
Action mechanism: glucagon receptor agonist. HM12525A is an oxyntomodulin-based therapy (GLP-1/glucagon receptor dual agonist) that has shown evidence of improving multiple metabolic parameters that lead to improved blood glucose, body weight, and insulin sensitivity. This asset has the potential, as a once weekly therapy, to be a best-in-class oxyntomodulin-based therapy.
Disease: diabetes
Details: * On November 9, 2015, Janssen Pharmaceuticals announced that it has obtained worldwide rights, excluding China and Korea , to develop and commercialize oxyntomodulin-based therapies including HM12525A, a biologic that is completing Phase 1 and expected to enter Phase 2 studies next year, from Hanmi Pharmaceutical. The agreement is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions.
Financial terms:
Latest news:
